Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.

<description>&lt;p&gt;&lt;span style="font-size: 13px; font-family: arial, sans, sans-serif;"&gt;Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.&lt;/span&gt;&lt;/p&gt;</description>

Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.

Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?

What puts you at risk for inherited kidney cancer? Dr. Nizar Tannir discusses the signs doctors look for to determine if a kidney cancer patient should be screened for a familial syndrome.

<description>&lt;p&gt;&lt;span style="font-size: 13px; font-family: arial, sans, sans-serif;"&gt;What puts you at risk for inherited kidney cancer? Dr. Nizar Tannir discusses the signs doctors look for to determine if a kidney cancer patient should be screened for a familial syndrome.&lt;/span&gt;&lt;/p&gt;</description>

What puts you at risk for inherited kidney cancer? Dr. Nizar Tannir discusses the signs doctors look for to determine if a kidney cancer patient should be screened for a familial syndrome.

Management of Rare Kidney Tumors

The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.

<description>&lt;p&gt;&lt;span style="font-size: 13px; font-family: arial, sans, sans-serif;"&gt;The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.&lt;/span&gt;&lt;/p&gt;</description>

The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.

Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation?

NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine what treatments may be most effective for them.

<description>&lt;p&gt;&lt;span style="font-size: 13px; font-family: arial, sans, sans-serif;"&gt;NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine what treatments may be most effective for them.&lt;/span&gt;&lt;/p&gt;</description>

NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine what treatments may be most effective for them.

NanoString Treatment for Kidney Cancer

Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.

<description>&lt;p&gt;&lt;span style="font-size: 13px; font-family: arial, sans, sans-serif;"&gt;Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.&lt;/span&gt;&lt;/p&gt;</description>

Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.

Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.

GRACEcast Lung Cancer Audio

Details

Recent Episodes